Epiomic Epidemiology Series: Fabry Disease Forecast in 8 Major Markets 2015-2025

October 2015 | 42 pages | ID: E4E1007DFC8EN
Black Swan Analysis limited

Abstracts

Fabry disease is a lysosomal storage disorder, caused by a genetic defect in the alpha-galactosidase-A gene (?GLA-gene), localized on the long arm of the X-chromosome (Xq22). This gene is essential in the breakdown of fatty substances, otherwise substances like globotriaosylceramide, will accumulate in the arteries, narrowing them and reducing blood flow around the body. It is a multi-system disorder characterised by dermatologic angiokeratoma corporis diffusum and purpura haemorrhagica nodularis, but also affects ocular, auditory, cardiac, digestive and renal systems.

This report provides the current prevalent population for Fabry Disease across 8 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil and Japan) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of Fabry disease have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for Fabry disease include:

• Angiokeratoma
• Cornea verticillata (corneal whorling)
• Hearing loss
• Tinnitus
• Proteinurea
• Cardiac hypertrophy & arrhythmias
• Sweating dysfunction

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

• Able to quantify patient populations in global Fabry disease’s market to target the development of future products, pricing strategies and launch plans.
• Gain further insight into the prevalence of the subdivided types of Fabry disease and identify patient segments with high potential.
• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
• Provide a level of understanding on the impact from specific co-morbid conditions on Fabry disease’s prevalent population.
• Identify sub-populations within Fabry Disease which require treatment.
• Gain an understanding of the specific markets that have the largest number of Fabry disease patients.

Contents

Introduction
Cause of the Disease
Risk Factors & Prevention
Diagnosis of the Disease
Variation by Geography/Ethnicity
Disease Prognosis &Clinical Course
Key Co-morbid Conditions /Features Associated with the Disease
Methodology for Quantification of Patient Numbers
Top-Line Prevalence for Fabry Disease
Hearing Loss in Fabry Disease
  Type of Hearing Loss
  Extent of Hearing Loss
Associated Co-morbid Conditions of Fabry Disease
  Renal & Urinary Conditions
  Cardiovascular Affected Conditions
  Dermatological Conditions
  Ophthalmic Conditions
Abbreviations and Acronyms used in the Report
Other Black Swan Analysis Publications
Black Swan Analysis Online Patient-Based Databases
Patient-Based Offering
Online Pricing Data and Platforms
References
Appendix

List Of Tables

LIST OF TABLES

WHO criteria for hearing impairment
Prevalence of Angina, total (000s)
Prevalence of Angina, males (000s)
Prevalence of Angina, females (000s)
Type of hearing loss in patients with Fabry disease, total (000s)
Extent of hearing loss in patients with Fabry disease, total (000s)
Prevalence of renal/urinary symptoms in patients with Fabry disease, total (000s)
Renal/urinary incompetence in patients with Fabry disease, total (000s)
Cardiac symptoms in patients with Fabry disease, total (000s)
Heart conditions in patients with Fabry disease, total (000s)
Dermatological symptoms in patients with Fabry disease, total (000s)
Sweat disorders in patients with Fabry disease, total (000s)
Capillary skin disorders in patients with Fabry disease, total (000s)
Ocular symptoms in patients with Fabry disease, total (000s)
Ocular conditions in patients with Fabry disease, total (000s)
Abbreviations and Acronyms used in the report
USA Prevalence of Fabry Disease by 5-yr age cohort, males (000s)
USA Prevalence of Fabry Disease by 5-yr age cohort, females (000s)
France Prevalence of Fabry Disease by 5-yr age cohort, males (000s)
France Prevalence of Fabry Disease by 5-yr age cohort, females (000s)
Germany Prevalence of Fabry Disease by 5-yr age cohort, males (000s)
Germany Prevalence of Fabry Disease by 5-yr age cohort, females (000s)
Italy Prevalence of Fabry Disease by 5-yr age cohort, males (000s)
Italy Prevalence of Fabry Disease by 5-yr age cohort, females (000s)
Spain Prevalence of Fabry Disease by 5-yr age cohort, males (000s)
Spain Prevalence of Fabry Disease by 5-yr age cohort, females (000s)
United Kingdom Prevalence of Fabry Disease by 5-yr age cohort, males (000s)
United Kingdom Prevalence of Fabry Disease by 5-yr age cohort, females (000s)
Brazil Prevalence of Fabry Disease by 5-yr age cohort, males (000s)
Brazil Prevalence of Fabry Disease by 5-yr age cohort, females (000s)
Japan Prevalence of Fabry Disease by 5-yr age cohort, males (000s)
Japan Prevalence of Fabry Disease by 5-yr age cohort, females (000s)